` PPBT (Purple Biotech Ltd) vs S&P 500 Comparison - Alpha Spread

P
PPBT
vs
S&P 500

Over the past 12 months, PPBT has underperformed S&P 500, delivering a return of -85% compared to the S&P 500's +17% growth.

Stocks Performance
PPBT vs S&P 500

Loading
PPBT
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PPBT vs S&P 500

Loading
PPBT
S&P 500
Difference
www.alphaspread.com

Performance By Year
PPBT vs S&P 500

Loading
PPBT
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Purple Biotech Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Purple Biotech Ltd
Glance View

Market Cap
144.1m USD
Industry
Pharmaceuticals

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

PPBT Intrinsic Value
2.37 USD
Overvaluation 44%
Intrinsic Value
Price
P
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett